Astrazeneca Pharma India Ltd vs Sandu Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8217 as of 30 Apr 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2023 .The P/E Ratio of Sandu Pharmaceuticals Ltd is 33.3 as of March 2023 . The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sandu Pharmaceuticals Ltd is ₹ 50.43 crore as of March 2023 . The revenue of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 14.14 crore as compare to the Dec '24 revenue of ₹ 18.4 crore. This represent the decline of -23.15% The ebitda of Astrazeneca Pharma India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sandu Pharmaceuticals Ltd for the Mar '25 is ₹ 0.52 crore as compare to the Dec '24 ebitda of ₹ 1.02 crore. This represent the decline of -49.02% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Sandu Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.33 crore over 4 quarters. This represents a CAGR of 94.12% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Sandu Pharmaceuticals Ltd changed from 36.33 % on March 2021 to 49.86 % on March 2025 . This represents a CAGR of 6.54% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd (SPL) was established in 1985.
The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU. SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.'94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations.
This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards.
Ayurvedic products have a very good market in India and abroad due to their minimal side effects. The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97.
Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Sandu Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Sandu Pharmaceuticals Ltd is 42 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd?

As of May 3, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Sandu Pharmaceuticals Ltd stock price is INR ₹44.0.

How do dividend payouts of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Sandu Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.